Plain-English translation of NCT07284797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing a new medication called to see how safe it is and how your body handles it. Researchers will give the medication to healthy volunteers and to people who have been diagnosed with certain autoimmune diseases—including inflammatory myopathy, systemic sclerosis, and Sjögren's disease. The goal is to find the right dose and learn about any side effects before larger studies are done.
Autoimmune diseases cause the body's immune system to attack its own tissues, leading to inflammation and damage. This medication is designed as a potential new treatment approach, and researchers need to test it carefully in humans for the first time to make sure it is safe enough to study further.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an injection under your skin (a subcutaneous injection). The study will gradually test increasing doses in different groups of participants to find the safest dose. You will have multiple visits where researchers will check your health, draw blood, and monitor how your body responds to the medication over time. The exact duration and number of visits will depend on which dose group you are assigned to, but Phase 1 studies typically last several months.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Xencor, Inc.
Enrollment target
~60 participants
Started
February 2026
Primary completion
October 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Noriko Iikuni, MD, PhD
Xencor, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.